Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/34661
Title: Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Authors: 
Keywords: 
Mesh: 
Issue Date: 29-Nov-2018
Citation: BMC Cancer.2018 Nov;(18)1:1185
Abstract: Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in routine practice.
PMID: 30497432
URI: https://hdl.handle.net/20.500.12530/34661
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC6267080.pdf1.6 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.